Open
Actively Recruiting
Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
About
Brief Summary
Omidubicel is an investigational therapy for patients with high-risk hematologic malignancies.
Primary Purpose
Study Type
Phase
Eligibility
Gender
Healthy Volunteers
Minimum Age
Maximum Age
Inclusion Criteria:
- Patients must be at least 12 years of age
- Applicable disease criteria
- Patients must have one or two partially HLA-matched CBUs
- Back-up stem cell source
- Sufficient physiological reserves
- Females of childbearing potential agree to use appropriate method of contraception
- Signed written informed consent
Exclusion Criteria:
- Extensive bone marrow fibrosis
- Donor specific anti-HLA antibodies
- Pregnancy
- Medically unsuitable for transplant
Join this Trial
Contact our clinical trial navigators for opportunities that may be suitable for you
Study Stats
Protocol No.
20-000358
Category
Leukemia
Lymphoma
Multiple Myeloma
Principal Investigator
Contact
Location
- UCLA Westwood